Immunovant マネジメント

マネジメント基準チェック /24

Immunovantの CEO はPete Salzmannで、 Dec2019年に任命され、の在任期間は 4.92年です。の年間総報酬は$ 8.55Mで、 8.2%給与と91.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.3%を直接所有しており、その価値は$ 11.81M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と4.9年です。

主要情報

Pete Salzmann

最高経営責任者

US$8.6m

報酬総額

CEO給与比率	8.2%
CEO在任期間	4.9yrs
CEOの所有権	0.3%
経営陣の平均在職期間	3.1yrs
取締役会の平均在任期間	4.9yrs

経営陣の近況

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

CEO報酬分析

Immunovant の収益と比較して、Pete Salzmann の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$323m
Jun 30 2024	n/a	n/a	-US$273m
Mar 31 2024	US$9m	US$700k	-US$259m
Dec 31 2023	n/a	n/a	-US$243m
Sep 30 2023	n/a	n/a	-US$255m
Jun 30 2023	n/a	n/a	-US$245m
Mar 31 2023	US$6m	US$625k	-US$211m
Dec 31 2022	n/a	n/a	-US$199m
Sep 30 2022	n/a	n/a	-US$177m
Jun 30 2022	n/a	n/a	-US$167m
Mar 31 2022	US$6m	US$600k	-US$157m
Dec 31 2021	n/a	n/a	-US$138m
Sep 30 2021	n/a	n/a	-US$128m
Jun 30 2021	n/a	n/a	-US$111m
Mar 31 2021	US$15m	US$567k	-US$107m
Dec 31 2020	n/a	n/a	-US$100m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	US$9m	US$361k	-US$66m

報酬と市場: Peteの総報酬 ($USD 8.55M ) は、 US市場 ($USD 6.56M ) の同規模の企業の平均を上回っています。

報酬と収益: Peteの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Pete Salzmann (56 yo)

4.9yrs

在職期間

US$8,552,430

報酬

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer and Director of Immunovant, Inc. since December 2019. Dr. Salzmann has served as a member of Immunovant Sciences Ltd.’s b...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frank Torti	Executive Chairperson of the Board	4.9yrs	US$3.69m	0.014% $ 537.6k
Peter Salzmann	CEO & Director	4.9yrs	US$8.55m	0.30% $ 11.8m
Jay Stout	Chief Technology Officer	1.6yrs	US$4.04m	データなし
Eva Barnett	Chief Financial Officer	3.1yrs	US$2.07m	0.091% $ 3.6m
Melanie Gloria	Chief Operating Officer	no data	データなし	データなし
Mark Levine	Chief Legal Officer & Corporate Secretary	2.8yrs	データなし	0.076% $ 3.0m
Lauren Schrier	Vice President of Marketing	4.8yrs	データなし	データなし
Christine Blodgett	Senior Vice President of Human Resources	no data	データなし	データなし
William Macias	Chief Medical Officer	3.4yrs	US$1.92m	0.13% $ 5.3m
Andy Deig	Senior Vice President of Strategic Finance	no data	データなし	データなし
Michael Geffner	Chief Medical Officer	less than a year	データなし	0.016% $ 638.2k
Julie Kirschling	Senior Vice President of Program & Alliance Management	no data	データなし	データなし

3.1yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: IMVTの経営陣は経験豊富であると考えられます ( 3.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Frank Torti	Executive Chairperson of the Board	4.9yrs	US$3.69m	0.014% $ 537.6k
Peter Salzmann	CEO & Director	4.9yrs	US$8.55m	0.30% $ 11.8m
George Migausky	Independent Director	4.9yrs	US$291.32k	0.027% $ 1.0m
Andrew Fromkin	Director	5.1yrs	US$445.00k	0.012% $ 479.6k
Atul Pande	Independent Director	5.1yrs	US$287.62k	0.022% $ 869.3k
Douglas Hughes	Independent Director	4.9yrs	US$436.30k	0.012% $ 490.3k
Eric Venker	Director	4.8yrs	US$55.00k	データなし

4.9yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: IMVTの取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

Immunovant マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

CEO & Director recently sold US$480k worth of stock

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

Recent updates

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Price target decreased to US$10.78

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Price target decreased to US$11.25

Chief Medical Officer recently sold US$222k worth of stock

Price target decreased to US$12.25

Immunovant, Inc. Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Independent Director recently bought US$150k worth of stock

Independent Director recently bought US$54k worth of stock

Price target decreased to US$19.86

マネジメント基準チェック /24